The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are human herpesviruses (HHV) that
are common in humans. Primary EBV and CMV infections mostly are asymptomatic but can …

Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …

Objective This study was performed to identify risk factors for acute cellular rejection after
liver transplantation (LT). Methods Consecutive LT recipients who underwent surgery in our …

Introduction: Traditional inactivated and protein vaccines generate strong antibodies, but
struggle to generate T cell responses. Attenuated pathogen vaccines generate both, but risk …

Emergence of drug-resistance to all FDA-approved antiherpesvirus agents is an increasing
concern in immunocompromised patients. Herpesvirus DNA polymerase (DNApol) is …

Human cytomegalovirus (HCMV) can cause severe disease in patients with compromised or
immature immune systems. Currently approved pharmacotherapies for the treatment of …

Cytomegalovirus (CMV) infection is a common complication of liver trans-plantation in
children. The CMV serostatus of recipients and donors is the primary risk factor, and …

Background: Information on the risk factors, particularly kidney function, and impact of long-
term cardiovascular events (CVE) after liver transplantation (LT) remains scarce. Methods …

Background Liver transplant recipients are prone to both short-term and long-term
complications and may present to any emergency department. Objective This narrative …